Bioinformatics and Advanced Analytics Powering Drug Discovery

Share this:
Published: 12 May 2017

Personalized medicine has brought forth a new avenue for innovation. Currently, genomics is being accelerated into extensive use across drug development and drug discovery. The capability of genomics has brought about the resurgence of biomarkers that could effective patient stratification, ensuring the right drugs are developed to treat a specific type of disease. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Precision oncology, genomics, personalized medicine, glycoproteomics, circulating tumor cells, biomarkers, ALS, malaria


Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..